Company History
Medicilon History
2020
-Medicilon has established a tumor immune service platform to provide oncolytic viruses, RNAi, CAR-T and vaccine research technology
-Medicilon established the PROTAC drug discovery technology platform
-DEL DNA coding small molecule compound library screening technology
-Chemical AI technology
-CDMO platform
-Nanhui park
2019
– Medicilon Inc. – Announcement of an IPO on Sci-Tech Innovation Board in China
– (stock code : 688202.SH)
– Fifteenth Anniversary Celebration Series
– Passed the Review of GLP & AAALAC
2018
– Nanhui R&D Center Officially Operate
– IND approved in Sweden
2017
– Medicilon established the preclinical cardiac safety assessment study platform
– Established the clinical BE biological analysis platform
– Established an inhalation and ophthalmic administration evaluation platform
– Established the registration and declaration service platform
– Expand the Tumor Center
– The introduction of new high-throughput Biacore experimental instrument
– The introduction of new multiple LC-MS / MS mass spectrometers
2016
– Medicilon was awarded as “Shanghai Academicians and Experts Workstation Qualified Unit”
– Medicilon completed the construction of preparation center and microbial laboratory
– Medicilon completed the construction of preparation center and GMP pilot plant
– Established the tumor immunology service platform
– Established the biotechnology drug and bioanalysis service platform
– Established the ADC (Antibody Drug Conjugate) preclinical service platform
– Establish a “Generic Drug Quality Consistency Assessment Service Platform”
– The introduction of the new mass spectrometer, Triple Quad 6500
– The introduction of the new IVIS Lumina III Imaging System
2015
– Expansion of the New Laboratory Area with 10,000 square meters
– Medicilon held first Congress of Science and Technology Association
2014
– Tenth Anniversary Celebration Series
– Approved the Establishment of Academicians and Experts Workstations
– Expansion of the New Laboratory Area with 10,000 square meters
– Expand Isotope Biomarker Services
– Passed the Review of CFDA GLP
2013
Successfully introduce new foreign drugs to domestic pharmaceutical companies
Establishment of new three party collaboration model: Foreign Enterprise – Medicilon – Domestic Pharmaceutical Company
Chinese government officially approve Shanghai Medicilon Inc. become the holding company of MPI Preclinical Research (Shanghai) LLC.
2012
– Participate the filming of “DaDaoTongXing” as the representative of Shanghai high-tech enterprises
– Provide the complete application for both CFDA and US FDA IND filing
– Three party collaboration to promote the drug development process
– Undertake the “Twelve Five Year Project” on creating new drug task
– GLP is successfully reviewed by both US FDA and CFDA
2011
– China’s SFDA officially approved Medicilon’s GLP Certification
– Medicilon recognized as a “Cultivated Little Giant Enterprise” in Shanghai’s High Technology Industry
2010
– Fortune Capital signed investment agreement with Medicilon aimed for IPO in China
– Medicilon is recognized as one of the top seven integrated services CRO in China in Citi Investment’s report
– Medicilon’s “Shanghai Isotope Drug Metabolism Professional and Technical Services Platform”, was selected as the first batch of “Shanghai Professional and Technical Service Platform”
2009
– Medicilon acquires international AAALAC Accreditation
– Medicilon preclinical research facilities compliance with US GLP standard
– “Protein-crystallography-based Drug Discovery and Screen Platform” of Medicilon was listed in Shanghai R&D Public
– “NHP Experimental Service Platform” of Medicilon/MPI was listed in Shanghai R&D Public Service Platforms
– Medicilon established CMC platform
2008
– Animal facility in Medicilon approved by Shanghai Animal Committee, was issued the License of Laboratory Animal (Rat, Mouse, Dog and Monkey).
– The joint venture company, Medicilon Preclinical Research, registered in Shanghai, begins to provide preclinical GLP services
– Laboratories expanded to 20,000 square meters in the Chuansha campus which include the largest animal facility (40 animal rooms) in Shanghai
2007
– Joint Venture agreement between Shanghai Medicilon Inc. and MPI Research signed
– Commenced non-GLP preclinical research and projects
2006
– Medicilon was acknowledged as Hi-tech Enterprise by Shanghai Science Commission
2005
– Trademark “美迪西” (Medicilon Inc.) approved by Chinese government
– Animal facilities were issued their respective licenses (Rat, Mouse, Rabbit, Dog and Non-human primates)
– Established the first chemical synthesis FTE team
2004
– Medicilon registered in Shanghai, Laboratory construction in Zhangjiang Hi-tech Park
– Initially provided Chemistry and Bioanalysis Services
– First LC/MC/MC was imported for pharmacokinetics services